Last reviewed · How we verify

NCT04811313

Impact of Tranexamic Acid Use on Blood Loss and Transfusion Rates After Hip Reconstruction in Children, A Randomized Controlled Trial

Recruiting now NA Last updated 14 November 2025
What this trial tests

NA trial testing Tranexamic acid in Intraoperative Blood Loss in 400 participants. Currently enrolling.

Timeline
3 April 2025
Primary endpoint
1 January 2026
1 March 2026

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment400
Start date3 April 2025
Primary completion1 January 2026
Estimated completion1 March 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 1 to 18, any sex, with Intraoperative Blood Loss or Pediatric. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Surgical hip reconstruction reduces the hip joint through soft tissue releases and osteotomies of the femur and/or pelvis. Blood loss and subsequent blood transfusion are normal consequences of hip reconstruction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tranexamic acid

Trials testing the same drug.

Other recruiting trials for Intraoperative Blood Loss

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04811313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing